Evaluation of Relation between HbA1c Level with Cognitive Disorders and Depression in Type 2 Diabetes Mellitus Patients

BACKGROUND:

The role of HbA1c level in cognition decline and depression in type 2 diabetic patients is reported in some studies.

AIM:

We evaluated the possible significant relationship between HbA1c level and cognition decline and depression in type 2 diabetic patients.

MATERIAL AND METHODS:

This descriptive-analytic study was performed on 512 patients with a different HbA1c level and ages range. All subjects were administered a structured clinical interview. Cognitive functions and depressive disorders were assessed through the Mini-Mental Status Exam (MMSE) and Patient Health Questionnaire-9 (PHQ-9) respectively. Chi-square test was used for relationships between variables.

RESULTS:

HbA1c mean in all patients was 7.58%. MMSE score mean in total was 27.28. 83.3% of patients had a depressive disorder, and 8.59% of patients had an MMSE score < 24. There was no significant relationship between HbA1c level and cognitive problems, but there was a significant relationship between recent memory declines with the level of HbA1c (P = 0.03). Also, there was no significant relationship between attention-deficit with HbA1c level.

CONCLUSION:

Our finding provides that even though there is no significant difference between HbA1c level and cognitive problems and depression, recent memory state in these patients are more affected than the normal population and these patients have a worse state of depressive disorders.

Tamoxifen Induces Apoptosis of Leishmania major Promastigotes in Vitro

Tamoxifen is an antagonist of the estrogen receptor and currently used for the treatment of breast cancer. The current treatment of cutaneous leishmaniasis with pentavalent antimony compounds is not satisfactory. Therefore, in this study, due to its antileishmanial activity, effects of tamoxifen on the growth of promastigotes and amastigotes of Leishmania major Iranian strain were evaluated in vitro. Promastigotes and amastigotes were treated with different concentrations (1, 5, 10, 20, and 50 μg/ml) and time periods (24, 48, and 72 hr) of tamoxifen. After tamoxifen treatment, MTT assay (3-[4,5-dimethylthiazol-2-yl]-2,5 biphenyl tetrazolium bromide assay) was used to determine the percentage of live parasites and Graph Pad Prism software to calculate IC50. Flow cytometry was applied to investigate the induction of tamoxifen-induced apoptosis in promastigotes. The half maximal inhibitory concentration (IC50) of tamoxifen on promastigotes was 2.6 μg/ml after 24 hr treatment. Flow cytometry analysis showed that tamoxifen induced early and late apoptosis in Leishmania promastigotes. While after 48 hr in control group the apoptosis was 2.0%, the 50 µg/L concentration of tamoxifen increased it to 59.7%. Based on the in vitro antileishmanial effect, tamoxifen might be used for leishmaniasis treatment; however, further researches on in vivo effects of tamoxifen in animal models are needed.